相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
Ila Tamaskar et al.
JOURNAL OF UROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Hypoxia inducible factor-1-independent pathways in tumor angiogenesis
Yusuke Mizukami et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)